Related Experiment Video
Updated: Jun 24, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
Thrombolytic therapy for deep vein thrombosis: potential application of plasmin
1David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1795, USA. vmarder@mednet.ucla.edu
Abstract:
Plasmin is the prototype of a distinct class of "direct-acting" fibrinolytic agents, with biochemical and physiological attributes that are favorable for catheter-delivered thrombolytic therapy. Our studies indicate that plasmin is superior to plasminogen activators for hemostatic safety and thrombolytic efficacy in experimental models, and that plasmin has potential to avoid the bleeding risk that accompanies therapy of deep vein thrombosis with currently-used thrombolytic agents.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Venous Thrombosis I: Introduction
Pulmonary Embolism III: Nursing Management
